Views & Analysis Rare diseases and orphan drugs need digital innovation mHealth tech can provide longer-term monitoring for clinical trials.
News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
News Biogen/Ionis could launch rare disease drug within weeks Companies prepare for launch of Spinraza after phase 3 success.
Views & Analysis Tunnah’s musings: Rare diseases hold key to future of drug d... The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.
Views & Analysis Every voice matters: demand assessment in rare diseases A market research approach suitable for the complexities found in rare diseases.
Views & Analysis Flexible models for better access Which initiatives are the most likely to bring life-changing therapies to patients?
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
